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Abstract: Radiation therapy is the foundation for treatment of locally advanced non-small cell lung
cancer (NSCLC), a disease that is often inoperable and has limited long term survival. Local control
of disease is strongly linked to patient survival and continues to be problematic despite continued
attempts at changing the dose and fractionation of radiation delivered. Technological advancements such
as 4-dimensional computed tomography (CT) based planning, positron emission tomography (PET)
based target delineation, and daily image guidance have allowed for ever more accurate and conformal
treatments. A limit to dose escalation with conventional fractions of 2 Gy once per day appears to have
been reached at 60 Gy in the randomized trial Radiation Therapy Oncology Group (RTOG) 0617.
Higher doses were surprisingly associated with worse overall survival. Approaches other than conventional
dose escalation have been explored to better control disease including accelerating treatment to limit
tumor repopulation both with hyperfractionation and its multiple small (<2 Gy) fractions each day and
with hypofractionation and its single larger (>2 Gy) fraction each day. These accelerated regimens are
increasingly being used with concurrent chemotherapy, and multiple institutions have reported it as
tolerable. Tailoring treatment to individual patient disease and normal anatomic characteristics has been
explored with isotoxic dose escalation up to the tolerance of organs at risk, with both hyperfractionation
and hypofractionation. Metabolic imaging during and after treatment is increasingly being used to boost
doses to residual disease. Boost doses have included moderate hypofractionation of 2–4 Gy, and more
recently extreme hypofractionation with stereotactic body radiation therapy (SBRT). In spite of all these
changes in dose and fractionation, lung and cardiovascular toxicity remain obstacles that limit disease
control and patient survival.
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Introduction
Lung cancer has long been the most common cause of cancer
death worldwide, claiming 1.7 million lives annually (1).
Non-small cell is the most common type of lung cancer
diagnosed, and approximately 25% of patients will present
with locally advanced disease (2). Locally advanced disease
is typically defined as American Joint Committee on
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Cancer stage III, with unresectable primary tumors (T4)
or involvement of lymph nodes in the mediastinum (N2)
or supraclavicular fossa (N3) (3). While locally advanced
disease is curable, patient outcomes unfortunately remain
poor despite both radiation therapy, chemotherapy, and
now immunotherapy having improved over time.
The foundation of treatment for locally advanced disease
is radiation therapy. Radiation is usually combined with
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concurrent platinum-based chemotherapy, as several trials
and a meta-analysis have shown improved overall survival
and local control with concurrent rather than sequential
treatment (4). Control of disease with concurrent therapy
remains challenging, however, with 2-year progression
free survival at just 20–30%. Though the development of
distant metastases is most common with approximately
50% of patients experiencing this at 2 years, 30–40% of
patients also develop local failure in 2 years (5). Resection
after concurrent chemoradiation therapy show that this
combination of radiation and chemotherapy only leads to
complete response in 35–45% of patients (6,7). This review
will focus on escalation of the total radiation dose used for
treatment, as well as changes to dose and fractionation that
are being explored in attempts to improve local control and
outcomes in locally advanced disease.
Conventional fractionation
Radiation therapy for locally advanced non-small cell lung
cancer (NSCLC) is most commonly given in fractions of
1.8 to 2.0 Gy once a day for five days a week with external
beams. Radiation Therapy Oncology Group (RTOG)
7301 established a dose of 60 Gy as the standard, after
escalating the total dose from 40 Gy in a split course, then
to continuous delivery from 40, to 50, and finally to 60 Gy,
with the higher doses having higher intrathoracic tumor
control rates (8). It should be noted that this dose escalation
was done in the two dimensional era when plans were
made on based upon X-rays. This was before computed
tomography (CT) scanners were used in the clinic. Since
then, advances in radiation treatment have included three
dimensional CT-based conformal treatment planning,
the use of positron emission tomography (PET) for more
accurate staging and targeting, and accounting for tumor
motion during treatment.
Traditionally, external beam radiation therapy for locally
advanced NSCLC targeted the primary tumor as well as
the ipsilateral hilar and mediastinal nodal stations, and
sometimes even the supraclavicular fossa. This was done
even without evidence of involvement in these regions and
is known as elective nodal irradiation. This was done to
control any microscopic disease in areas felt to be high risk
for regional metastases. The concern with elective nodal
irradiation, however, is that it will limit dose escalation as
the larger volume irradiated will lead to otherwise avoidable
pulmonary, cardiovascular, and esophageal toxicity. Three
randomized trials on its use and several cohorts have been
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reported. A meta-analysis of these studies shows the overall
incidence of elective nodal failure was 5.5% without elective
nodal irradiation and 3.4% with it (P=0.64 assuming a fixedeffects mode) (9). Given this lack of a significant difference,
radiation is now most often prescribed only to gross disease
that is enlarged on CT or hypermetabolic on PET.
Conventional dose escalation
In attempts to improve local control, radiation dose
escalation with conventional fractionation and concurrent
chemotherapy was performed by several groups in phase I
and II trials. RTOG 0117 escalated to 75.25 Gy in 2.15 Gy
daily fractions prescribed to the isocenter. Three of the eight
patients who received 75.25 Gy developed dose-limiting
pulmonary toxicity, one of which was fatal. The maximum
tolerated radiation dose was therefore determined to be
74 Gy in 2 Gy fractions (10). North Central Cancer
Treatment Group (NCCTG) 0028 escalated from
70 Gy up in 4 Gy increments. Similar to RTOG 0117, the
maximum tolerated dose was also determined to be 74 Gy.
Two of four patients experienced dose limiting pneumonitis
at 78 Gy (11). The University of North Carolina first
escalated from 60 to 74 Gy both with limited elective nodal
radiation and with induction and concurrent chemotherapy,
then later from 74 to 90 Gy showing grade 3 or greater
late complications in 22% of patients (12). Cancer and
Leukemia Group B (CALGB) 30105 was a phase II trial
treating at 74 Gy and randomizing between gemcitabine
and paclitaxel used in both induction and concurrent
treatment (13). Aside from the gemcitabine arm of this trial
which closed early due to high toxicity, most of these trials
showed a median survival of around 2 years.
These trials then led to the multi-institutional
randomized controlled phase III trial RTOG 0617. In this
2×2 factorial design trial, patients with stage III NSCLC all
received weekly carboplatin and paclitaxel chemotherapy
with concurrent radiation in 2 Gy per once daily fraction
followed by two cycles of consolidative chemotherapy after
the completion of radiation. Patients were randomized
to receive either 60 or 74 Gy and to receive this with
or without cetuximab. At the first interim analysis, the
monitoring committee established that the trial had crossed
the futility boundary with respect to the 74 Gy arm, and
this high dose arm was closed. The trial continued accruing
only at the 60 Gy arm. At the third interim analysis, it was
established that the cetuximab arm had also crossed the
futility boundary.
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The published results of 0617 showed significant
increased rates of death in the 74 Gy arm, challenging the
assumption established in the earlier phase I/II studies that
radiotherapy dose escalation with conventional fractionation
and concurrent chemotherapy will improve outcomes (14).
The median survival was 28.7 months in the 60 Gy arm
versus 19.5 months in the 74 Gy arm (P=0.0007; HR 1.56,
95% CI: 1.19–2.06) (5). There was a 37% increased risk of
local failure in the high dose arms (P=0.0319, HR 1.37, 95%
CI: 0.99–1.89). There was no difference in severe (Common
Terminology Criteria for Adverse Events grade ≥3) toxic
effects overall, in severe pulmonary events specifically, or in
severe radiation pneumonitis between the radiation therapy
dose groups. Severe esophagitis was more common in the
high-dose group (21% vs. 16%, P<0.0001). On multivariate
analyses, factors predicting worse overall survival were
maximum esophagitis grade, planning target volume size,
heart dose, and radiation dose.
The poor survival with treatment to 74 Gy has been
attributed to several causes. Treatment-related deaths were
more common in the high-dose group than in the lowdose group (10 vs. 2), but this comparison did not reach
statistical significance. Concurrent chemotherapy was
more difficult to complete in the high-dose group than
in the low-dose group. Rates of protocol non-compliance
were greater in the high-dose arm, 26% vs. 17% (P=0.02),
as were treatment delays. Radiation therapy planning was
more likely to be non-compliant in the high-dose group,
and planning target volume coverage by the 95% isodose
line was poorer in the high-dose group. Concerns that noncompliance in the high-dose groups produced these results
led to analysis of overall survival only in those patients with
radiation plans compliant with the protocol; nevertheless,
overall survival was still better in the standard-dose groups
than in the high-dose groups.
The fact that heart dose was a significant predictor
of overall survival on the multivariate analysis of RTOG
0617 strongly suggests that it is not only dose to tumor
that should be considered in future studies. While further
analysis of RTOG 0617 is pending, three retrospective
studies also suggest heart dose can predict overall survival
and cardiac events. The largest with 322 patients identified
higher doses as important for overall survival and generated
a new and more conservative heart constraint of V50 <25%,
or letting no more than 25% of the heart exceed 50 Gy (15).
Two smaller series of 125 and 112 patients focused on
cardiac events and showed mean heart dose was important
(16,17). A secondary analysis of RTOG 0617 showed that
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patients treated at centers with high trial accrual, a potential
surrogate for number of NSCLC patients treated annually,
had better survival, lower esophageal and heart doses,
and lower lethal events (18). Radiation associated cardiac
toxicity after treatment of locally advanced NSCLC may
occur earlier than historically understood, and thus heart
doses should be minimized with any future attempts at dose
escalation.
Likely due to PET staging and modern radiation
therapy techniques, the 28.7-month median survival in
the 60 Gy arm was longer than that seen in previous
studies, was better than anticipated, and set a new
benchmark for patients with locally advanced NSCLC
receiving concurrent chemotherapy and radiation therapy.
Consequently, current trials in the United States such
as RTOG 1306 and National Research Group (NRG)
L001 have adopted 60 Gy as the standard, as well as the
American Society for Radiation Oncology (ASTRO) in
its guidelines (19). The National Comprehensive Cancer
Network (NCCN) guidelines in the United States now
suggest definitive radiation should be 60 to 70 Gy (20).
The European Society for Medical Oncology guidelines
state that “dose in excess of 66 Gy is not recommended
outside trials” (21). The Cancer Council of Australia (CCA)
says that radiation dose “should be at least 60 Gy assuming
that dose-volume constraints on organs at risk are met”
and that “74 Gy is not better than 60 Gy and may be
potentially harmful” (22). Many other national guidelines,
such as China’s from 2015 (23), do not make explicit dose
recommendations yet.
Hyperfractionation
Not all patients will be felt fit enough to tolerate concurrent
treatment with chemotherapy, however, and many of
those same national guidelines recommend accelerated
hyperfractionation in such patients. The National Institute
for Health and Care Excellence (NICE) and CCA both
recommend continuous hyperfractionated accelerated
radiation therapy (CHART) when only radiation therapy
will be used as treatment. Acceleration refers to finishing
treatment more rapidly than is done conventionally.
Hyperfractionation refers to dividing treatment into
smaller doses more than once a day. The CHART trial
compared 36 fractions of 1.5 Gy given three times per
day to a total dose of 54 Gy in 12 consecutive days with
30 fractions of 2 Gy once a day to a total dose of 60 Gy in
6 weeks. CHART improved 2-year overall survival from
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20% to 29% (P=0.008). The majority of patients (81%) had
squamous cell cancer, and in such patients, 2-year overall
survival improved from 20% to 33% (P=0.0007) (24).
This regimen has never been directly compared to
conventional chemoradiation in a randomized trial,
however. An individual patient data meta-analysis showed
that hyperfractionation improved overall survival by 2.5%
at 5 years without improving progression free survival when
compared to conventionally fractionated radiation alone.
This came at the risk of worse acute esophageal toxicity
(odds ratio of 2.44 in NSCLC) (25). The theory is that
prolongation of treatment results in increased tumor cell
repopulation (26), and has been proposed as one reason why
the high dose arm of RTOG 0617 failed.
However, the CHART regimen is inconvenient as many
centers are closed on weekends, and it often requires that
the patients be hospitalized. The randomized phase III
CHARTWEL (continuous hyperfractionated accelerated
radiotherapy weekend less) looked at 60 Gy in 40 fractions
over 2.5 weeks versus 66 Gy in 33 fractions over 6.5 weeks.
In contrast to CHART, CHARTWEL showed no difference
in overall survival and local tumor control. Exploratory
analysis suggested trends for improved local control with
hyperfractionation for higher stages of disease and after
neoadjuvant chemotherapy. Histology did not affect
control, and it should be noted that 58% of patients had
squamous cell cancers, in contrast to the 81% in CHART
where hyperfractionation showed the most promise in this
histology. Another potential explanation for the lack of
difference in overall survival was the fact that total radiation
doses were 10% higher in both arms of CHARTWEL
when compared to CHART (27).
Hyperfractionated radiation with concurrent
chemotherapy has also been compared to the combination
with conventional radiation. A 2×2 trial randomizing 60 Gy
in 30 fractions in either 6 weeks once a day or 3 weeks
twice a day with or without concurrent carboplatin showed
no statistically significant difference in local recurrence
or survival in all arms (28). RTOG 9410 showed that
concurrent chemotherapy with hyperfractionated radiation
to 69.6 Gy had statistically similar 5-year overall survival
when compared to conventional chemoradiation to 63 Gy,
13% vs. 16% (P=0.46). Grade 3 esophagitis was statistically
worse at 45% with hyperfractionation, double that of 22%
with conventional fractionation (P<0.001) (29). When
coupled with the logistical issues of delivering multiple
fractions per day and patient inconvenience, for patients
felt fit enough for concurrent treatment, conventional
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fractionation became standard in future trials.
Hypofractionation
Most recent studies have investigated accelerating
treatment with hypofractionation with larger radiation
d o s e s d e l i v e r e d o n c e p e r d a y, r a t h e r t h a n w i t h
hyperfractionation and its smaller doses delivered more
than once per day. Concerns about serious toxicity delayed
exploration of hypofractionation until technology such
as CT based planning, daily image guidance, and gating
became widespread. Most reports have been for modest
hypofractionation of 2–3 Gy per fraction. In patients
receiving radiation alone, three studies comparing standard
fractionation to hypofractionation did not report any
significant differences in toxicity or disease outcomes
(30-32). In a review of 22 studies of hypofractionated
radiation alone, Kaster et al. found the weighted mean acute
toxicity in the esophagus and lung being 1.9% and 1.2%
respectively. Late toxicity was also low at 1.4% and 6.9%.
Two-year overall survival ranged from 18% to 42%. There
was a moderate linear relationship between biologically
effective lesional dose (BED10): for every 1 Gy increase
in BED10, there was an absolute overall survival benefit
ranging from 0.36% to 0.70% (33). This is similar to the
results found by Machtay et al. with conventional radiation
where a 1 Gy increase in BED resulted in a 4% relative
improvement in survival (14), with in the context of 15%
long-term survival, is an absolute improvement of 0.6%.
Hypofractionation may allow for better outcomes by
increasing BED without lengthening treatment time and
thereby preventing cancer cell repopulation. Studies of
modest hypofractionation with concurrent chemotherapy
are fewer and mostly single arm, single institution studies.
In the same systemic review by Kaster et al., 15 studies
of hypofractionated radiation therapy with concurrent
chemotherapy were found. The weighted mean acute
toxicity in the esophagus and lung was 14.9% and 7.9%
respectively, and for weighted mean late toxicity in the
esophagus and lung, 6.6% and 12.2%. In comparison,
RTOG 0617 showed acute grade 3 esophagitis in 7%
and grade 3 pneumonitis in 4% with late toxicity rates
<1% for both. Two-year overall survival with concurrent
hypofractionation ranged from 24% to 58%. The 2-year
overall survival in RTOG 0617’s standard arm was 58% (5).
In the United Kingdom, 55 Gy in 20 fractions of 2.75 Gy is
the most commonly used schedule, both with and without
concurrent systemic therapy (34).
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More aggressive hypofractionation to 4 Gy per fraction
has been also been explored in patients not felt fit for
concurrent chemotherapy. MD Anderson used protons
to escalate to 60 Gy cobalt-equivalent in 15 fractions
in a phase 1 trial. At a median follow-up of 13 months,
two of 25 patients experienced dose-limiting toxicities.
One treated to 52.5 Gy cobalt-equivalent in 15 fractions
developed a tracheoesophageal fistula after bevacizumab
was delivered for recurrent disease. The second developed
“possible” grade 3 radiation pneumonitis (35). This regimen
with protons is currently being explored with concurrent
chemotherapy in a phase I study at our institution
(NCT02172846).
As protons are not available at most centers, a phase 1
dose escalation study was later reported using photons at
University of Texas Southwestern in patients who were
not chemotherapy candidates. It enrolled 55 patients
divided between 50, 55, and 60 Gy, all in 15 fractions.
One patient developed grade 3 esophagitis, and 2 cases of
grade 3 dyspnea were felt related to therapy. There was
no association between fraction size and toxicity (P=0.24),
and the median overall survival was 6 months at all dose
levels (P=0.59) (36). This same group has presented in
abstract form an interim analysis from a randomized
phase III comparison of 60 Gy in 15 vs. 30 fractions of
image-guided photon radiation therapy in patients with a
Zubrod performance status of 2 or greater. Median overall
survival for the 48 patients evaluable was 11.5 months
with no statistical difference between conventional and
hypofractionated radiation treatment arms. Two deaths
from hypoxia with conventional radiation and 1 death
with hypofractionated radiation were possibly related to
treatment (37). Final results are pending, but the study
authors feel the results could potentially change the
paradigm of treatment for patients with locally advanced
disease receiving radiation alone due to poor performance
status.
Adapted therapy
Rather than prescribing the same fixed dose to all
patients with locally advanced disease, isotoxic radiation
therapy is a novel approach which allows for personalized
treatment planning based on individual tumor and patient
characteristics. This tailored approach is heavily based
upon predefined organ at risk dose constraints. Treatment
plans are designed to give the maximum BED achievable
to the tumor target until the predefined dose constraints
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are reached. The increasing use of computer-based inverseplanned intensity modulated radiation therapy (IMRT)
makes this approach especially feasible.
One such approach with hyperfractionation,
individualized isotoxic accelerated radiotherapy (INDAR)
has been used for over a decade in the Netherlands. In
the first three weeks, 30 twice daily fractions of 1.5 Gy are
delivered. Next, 2 Gy fractions once a day are delivered
until a mean lung dose of 19 Gy is reached, with a total
ranging between 54 to 69 Gy in 5.5 weeks. The equivalent
conventional dose would be 72 Gy over 36 fractions. Long
term results showed that with sequential chemotherapy
and INDAR, the median survival was 23.6 months. For
comparison, the use of sequential chemotherapy and
conventional fractionation with the same group resulted in a
lower median survival of only 17.5 months (38). The use of
concurrent chemotherapy in a phase 1 study with INDAR
showed no dose limiting toxicity (39).
Instead of hyperfractionation, other institutions have
used isotoxic planning with hypofractionation. A single
institution phase I trial used 25 fractions ranging from 2.28
to 3.42 Gy (a total of 57 to 85.5 Gy) with IMRT. Total dose
was escalated according to each patient’s individual stratified
risk for radiation pneumonitis. The maximum tolerated
dose was predefined as the dose that theoretically would
result in ≤20% risk of severe toxicity. Grade 4 to 5 toxicity
was reached late in 6 of the 79 patients, and the maximum
tolerated dose was defined as 63.25 Gy in 25 fractions of
2.53 Gy each. These severe toxicities were due to damage
to the central and perihilar structures and corresponded to
dose to the proximal bronchial tree (40).
RTOG 1106, which recently completed accrual, coupled
the use of isotoxic hypofractionation with metabolic imaging
to adapt chemoradiation treatment for locally advanced
disease. The control arm was standard fractionation of
60 Gy in 30 fractions of 2 Gy each. In the experimental
arm, the first 21 fractions were 2.2 Gy each. The final nine
fractions were delivered only to residual disease seen on a
PET taken after fractions 18 or 19. Residual disease was
defined as any sites with metabolic activity at least 150%
that of the aortic arch. These final nine fractions could
range from 2.2–3.8 Gy per fraction, corresponding to a
range of 19.8 to 34.2 Gy. The highest achievable dose was
given while still respecting a mean lung dose of 20 Gy. The
theoretical maximum tumor dose was 80.4 Gy. Patients
were randomized 2:1 into the experimental arm with
stratification by stage, primary tumor size, and histology.
The primary objective was local control, and results are
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pending.
RTOG 1106 was based on studies from University
of Michigan which demonstrated that tumors decrease
more in metabolic activity than size during treatment.
Recently, this group reported on the results of a phase II
study of conformal radiation individualized to a fixed risk
of radiation-induced lung toxicity of 17.2% for grade 2 or
greater pneumonitis. Dose to residual tumor was adaptively
escalated to residual tumor on a mid-treatment PET up to a
total dose of 86 Gy in 30 fractions. The median tumor dose
delivered was 83 Gy over 30 fractions. The initial doses per
fraction were 2.1 to 2.85 Gy initially over 18–24 fractions,
then 2.85 to 5.0 Gy for the adaptive phase after the midtreatment PET. Most patients (93%) received concurrent
carboplatin and paclitaxel with consolidation chemotherapy.
With a median follow-up for surviving patients of
47 months, the 2-year rate of infield tumor control was
82% with a median overall survival of 25 months (41).
Rather than using mid-treatment imaging, other groups
have looked at boosting any residual disease after the
completion of conventional treatment with stereotactic
body radiation therapy (SBRT). SBRT has proven very
effective in early stage disease, especially in lesions far
from major airways and the mediastinum (42). With SBRT,
BEDs of at least 100 Gy total are typically delivered in
3– 5 fr a c t io n s w ith na rro w ma rg i ns . F o u r studies
have looked at a SBRT boost to residual disease after
conventional chemoradiation therapy to 50–60 Gy. In
these small series with limited follow-up, local control at
one year has been approximately 80% (43-46), comparable
to that of RTOG 0617, which was a mixed group that
contained patients who had a complete response. Of the
80 patients in these four studies of SBRT boosts, there
have been 5 (6.3%) lethal toxicities such as pulmonary
hemorrhage, particularly with boosts to central disease
near the main airways and mediastinum.
A multi-institutional trial has been proposed that would
use a SBRT boost to metabolically active residual disease
seen on PET-CT 2–4 weeks after chemoradiation treatment
completion (47). Patients with a complete response would
be observed. The benchmark for trial success would be
that in patients with residual disease after conventional
treatment, a SBRT boost would result in progressionfree survival of 20–30% at 2 years, matching that seen in
RTOG 0617. Now with immunotherapy recently showing
a progression free benefit when used after conventional
chemoradiation (48), SBRT becomes even more attractive
as a boost as it could theoretically better present tumor
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antigens and better serve as a potentiator of the patient’s
own immune system against their disease (49).
Conclusions
Locally advanced NSCLC remains a challenging disease
with significant mortality and complications. Efforts to
improve treatment outcomes have been only moderately
successful, but the combination of hypofractionation with
systemic therapy, individualized treatment adaptation, and
stereotactic boosts in the era of immunotherapy offers the
promise of further improvements.
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